Skip to Content

Join the 'Rayaldee' group to help and get support from people like you.

Rayaldee News

FDA Approves Rayaldee (calcifediol) to Treat Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Posted 22 Jun 2016 by Drugs.com

MIAMI--(BUSINESS WIRE) June 21, 2016 – OPKO Health, Inc. (NYSE:OPK) announced that the U.S. Food and Drug Administration (FDA) has approved Rayaldee (calcifediol) extended release capsules for the treatment of secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is a patented extended release product containing 30 mcg of a prohormone called calcifediol (25-hydroxyvitamin D3). "FDA's approval of Rayaldee represents an important milestone for OPKO," noted Dr. Phillip Frost, CEO and Chairman of OPKO. "Rayaldee is the first product to receive FDA approval for this important indication and is one of OPKO's many pharmaceutical products being developed for significant medical problems which will benefit from new treatment options." Results from two 26 week placebo controlled, ... Read more

Related support groups: Chronic Kidney Disease, Secondary Hyperparathyroidism, Rayaldee, Hyperparathyroidism Secondary to Renal Impairment, Calcifediol

Ask a Question

Further Information

Related Condition Support Groups

Hyperparathyroidism Secondary to Renal Impairment

Rayaldee Patient Information at Drugs.com